Extended Half-Life Coagulation Factors: A New Era in the Management of Hemophilia Patients

Despite effective factor replacement and various treatment schedules, there remain several challenges and unmet needs in the prophylactic treatment of hemophilia limiting its adoption and thereby posing an increased risk of spontaneous bleeding. In this regard, extended half-life (EHL) recombinant f...

Descripción completa

Detalles Bibliográficos
Autores principales: Ar, Muhlis Cem, Balkan, Can, Kavaklı, Kaan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Galenos Publishing 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6682782/
https://www.ncbi.nlm.nih.gov/pubmed/31088040
http://dx.doi.org/10.4274/tjh.galenos.2019.2018.0393

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6682782/
https://www.ncbi.nlm.nih.gov/pubmed/31088040
http://dx.doi.org/10.4274/tjh.galenos.2019.2018.0393

Ejemplares similares